From: Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
 | APRI> 1.5 (clinically relevant fibrosis) at baseline | |||||
---|---|---|---|---|---|---|
 | Univariate Analysis | Multivariable Analysis | ||||
Variable | OR | 95% CI | Wald p | OR | 95% CI | Wald p |
Hepatitis B | ||||||
 HBV negative |  | Reference |  |  | Reference |  |
 HBV positive | 3.18 | 2.10–4.84 | < 0.0001 | 3.08 | 1.99–4.78 | < 0.001 |
Hepatitis C | ||||||
 HCV negative |  | Reference |  |  | Reference |  |
 HCV positive | 4.77 | 3.43–6.63 | < 0.0001 | 4.55 | 3.26–6.35 | < 0.001 |
Baseline AIDS | ||||||
 No ADI ever |  | Reference |  |  |  |  |
 None before/at FARVDT | 1.49 | 0.74–2.98 | 0.44 |  | – |  |
  ≥ 1 before/at FARVDT | 1.63 | 0.77–3.46 |  |  |  |  |
Race | ||||||
 White |  | Reference |  |  |  |  |
 Black | 0.40 | 0.23–0.70 |  |  |  |  |
 Indigenous | 1.13 | 0.61–2.09 |  |  |  |  |
 Asian | 0.67 | 0.33–1.36 | 0.01 |  | – |  |
 Hispanic | 0.29 | 0.09–0.93 |  |  |  |  |
 Other | 1.35 | 0.66–2.80 |  |  |  |  |
 Unknown | 0.88 | 0.56–1.38 |  |  |  |  |
Birth sex | ||||||
 Female |  | Reference |  |  |  |  |
 Male | 1.06 | 0.70–1.62 | 0.78 |  | – |  |
Province | ||||||
 BC |  | Reference |  |  |  |  |
 ON | 0.47 | 0.32–0.68 | < 0.0001 |  | – |  |
 QC | 0.44 | 0.26–0.72 |  |  |  |  |
Years on ARV | 1.02 | 0.98–1.06 | 0.37 |  |  |  |
Age at first ARV | 1.02 | 1.01–1.04 | 0.003 | 1.02 | 1.00–1.04 | 0.01 |
MSM | 0.63 | 0.46–0.88 | 0.006 |  | – |  |
PWID | 3.47 | 2.49–4.82 | < 0.0001 |  | – |  |
Baseline HIV viral load (Log10 copies/mL) | ||||||
  < 4 |  | Reference |  |  | Reference |  |
 4–5 | 1.68 | 0.91–3.08 | 0.004 | 1.49 | 0.80–2.77 | 0.21 |
  > 5 | 2.46 | 1.35–4.48 |  | 2.15 | 1.16–3.97 | 0.02 |
Baseline CD4 count (cells/mm3) | ||||||
  > 500 |  | Reference |  |  |  |  |
 350–499 | 1.60 | 0.70–3.70 |  |  |  |  |
 200–349 | 1.82 | 0.85–3.92 | 0.0007 |  |  |  |
  ≤ 100 | 2.76 | 1.32–5.77 |  |  |  |  |